Endothelial-to-mesenchymal transition in pulmonary hypertension

Circulation

Volumn 131, Issue 11, 2015, Pages 1006-1018

  Ranchoux, Benoît ^a,b,c   Antigny, Fabrice ^a,b,c   Rucker Martin, Catherine ^a,b,c   Hautefort, Aurélie ^a,b,c   Péchoux, Christine ^d   Bogaard, Harm Jan ^f   Dorfmüller, Peter ^a,b,c,e   Remy, Séverine ^g   Lecerf, Florence ^a,b,c   Planté, Sylvie ^e   Chat, Sophie ^d   Fadel, Elie ^a,c,e   Houssaini, Amal ^h   Anegon, Ignacio ^g   Adnot, Serge ^h   Simonneau, Gerald ^a,b,c   Humbert, Marc ^a,b,c   Cohen Kaminsky, Sylvia ^a,b,c   Perros, Frédéric ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

^c Universite Paris Sud   (France)

^d INRA Institut National de la Recherche Agronomique   (France)

^e CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g Centre National de la Recherche Scientifique   (France)

^h UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

Animal; Bone morphogenetic protein receptors; Cardiovascular diseases; Epithelial mesenchymal transition; Human; Hypertension; Models; Neointima; Pulmonary; Sirolimus; Twist1 protein; Type ii; Vascular remodeling; Vimentin

Indexed keywords

MESSENGER RNA; RAPAMYCIN; VIMENTIN; ACTIN; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; MONOCROTALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL TRANSFORMATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENDOTHELIAL TO MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HUMAN TISSUE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; VASCULAR REMODELING; WESTERN BLOTTING; ANIMAL; ANOXIA; BIOSYNTHESIS; CELL CULTURE; CELL MOTION; CELL TRANSDIFFERENTIATION; CHEMICALLY INDUCED; COMPLICATION; DISEASE MODEL; ENDOTHELIUM CELL; GENE EXPRESSION PROFILING; GENETICS; LUNG; MESODERM; METABOLISM; MUTATION; PATHOLOGY; VASCULARIZATION;

ACTINS; ANIMALS; ANOXIA; BIOLOGICAL MARKERS; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CELL MOVEMENT; CELL TRANSDIFFERENTIATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; GENE EXPRESSION PROFILING; HUMANS; HYPERTENSION, PULMONARY; LUNG; MESODERM; MONOCROTALINE; MUTATION; RATS; RNA, MESSENGER; SIROLIMUS; VASCULAR REMODELING; VIMENTIN;

EID: 84929513782     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.114.008750     Document Type: Article

References (39)

1. O'Callaghan DS, Savale L, Montani D, Jaïs X, Sitbon O, Simonneau G, Humbert M. Treatment of pulmonary arterial hypertension with targeted therapies. Nat Rev Cardiol. 2011;8:526-538. doi: 10.1038/nrcardio.2011.104.
2. Pietra GG, Edwards WD, Kay JM, Rich S, Kernis J, Schloo B, Ayres SM, Bergofsky EH, Brundage BH, Detre KM. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation. 1989;80:1198-1206.
3. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, Voelkel NF, McMurtry IF, Oka M. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation. 2010;121:2747-2754. doi: 10.1161/CIRCULATIONAHA.109.927681.
4. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest. 2012;122:4306-4313. doi: 10.1172/JCI60658.
5. Arciniegas E, Frid MG, Douglas IS, Stenmark KR. Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2007;293:L1-L8. doi: 10.1152/ajplung.00378.2006.
6. Frid MG, Kale VA, Stenmark KR. Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation: in vitro analysis. Circ Res. 2002;90:1189-1196.
7. Arciniegas E, Neves CY, Carrillo LM, Zambrano EA, Ramírez R. Endothelial-mesenchymal transition occurs during embryonic pulmonary artery development. Endothelium. 2005;12:193-200. doi: 10.1080/10623320500227283.
8. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, Neilson EG, Sayegh MH, Izumo S, Kalluri R. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007;13:952-961. doi: 10.1038/nm1613.
9. He J, Xu Y, Koya D, Kanasaki K. Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease. Clin Exp Nephrol. 2013;17:488-497. doi: 10.1007/s10157-013-0781-0.
10. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, McMurtry IF, Stenmark KR, Thistlethwaite PA, Weissmann N, Yuan JX, Weir EK. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 suppl):S20-S31. doi: 10.1016/j.jacc.2009.04.018.
11. DeRuiter MC, Poelmann RE, VanMunsteren JC, Mironov V, Markwald RR, Gittenberger-de Groot AC. Embryonic endothelial cells transdifferentiate into mesenchymal cells expressing smooth muscle actins in vivo and in vitro. Circ Res. 1997;80:444-451.
12. Sakao S, Taraseviciene-Stewart L, Cool CD, Tada Y, Kasahara Y, Kurosu K, Tanabe N, Takiguchi Y, Tatsumi K, Kuriyama T, Voelkel NF. VEGF-R blockade causes endothelial cell apoptosis, expansion of surviving CD34+ precursor cells and transdifferentiation to smooth muscle-like and neuronal-like cells. FASEB J. 2007;21:3640-3652. doi: 10.1096/fj.07-8432com.
13. Zhu P, Huang L, Ge X, Yan F, Wu R, Ao Q. Transdifferentiation of pulmonary arteriolar endothelial cells into smooth muscle-like cells regulated by myocardin involved in hypoxia-induced pulmonary vascular remodelling. Int J Exp Pathol. 2006;87:463-474. doi: 10.1111/j.1365-2613.2006.00503.x.
14. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 suppl):S43-S54. doi: 10.1016/j.jacc.2009.04.012.
15. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol. 2009;297:L1013-L1032. doi: 10.1152/ajplung.00217.2009.
16. Díez M, Musri MM, Ferrer E, Barberà JA, Peinado VI. Endothelial progenitor cells undergo an endothelial-to-mesenchymal transition-like process mediated by TGFbetaRI. Cardiovasc Res. 2010;88:502-511. doi: 10.1093/cvr/cvq236.
17. Soubrier F, Chung WK, Machado R, Grünig E, Aldred M, Geraci M, Loyd JE, Elliott CG, Trembath RC, Newman JH, Humbert M. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62(25 suppl):D13-D21. doi: 10.1016/j.jacc.2013.10.035.
18. Potenta S, Zeisberg E, Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression. Br J Cancer. 2008;99:1375-1379. doi: 10.1038/sj.bjc.6604662.
19. Rabouille C. Quantitative aspects of immunogold labeling in embedded and nonembedded sections. Methods Mol Biol. 1999;117:125-144. doi: 10.1385/1-59259-201-5:125.
20. Price LC, Montani D, Tcherakian C, Dorfmüller P, Souza R, Gambaryan N, Chaumais MC, Shao DM, Simonneau G, Howard LS, Adcock IM, Wort SJ, Humbert M, Perros F. Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. Eur Respir J. 2011;37:813-822. doi: 10.1183/09031936.00028310.
21. Houssaini A, Abid S, Mouraret N, Wan F, Rideau D, Saker M, Marcos E, Tissot CM, Dubois-Randé JL, Amsellem V, Adnot S. Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension. Am J Respir Cell Mol Biol. 2013;48:568-577. doi: 10.1165/rcmb.2012-0429OC.
22. Bogaard HJ, Mizuno S, Guignabert C, Al Hussaini AA, Farkas D, Ruiter G, Kraskauskas D, Fadel E, Allegood JC, Humbert M, Vonk Noordegraaf A, Spiegel S, Farkas L, Voelkel NF. Copper dependence of angioproliferation in pulmonary arterial hypertension in rats and humans. Am J Respir Cell Mol Biol. 2012;46:582-591. doi: 10.1165/rcmb.2011-0296OC.
23. Nicolls MR, Mizuno S, Taraseviciene-Stewart L, Farkas L, Drake JI, Al Husseini A, Gomez-Arroyo JG, Voelkel NF, Bogaard HJ. New models of pulmonary hypertension based on VEGF receptor blockade-induced endothelial cell apoptosis. Pulm Circ. 2012;2:434-442. doi: 10.4103/2045-8932.105031.
24. Geurts AM, Cost GJ, Freyvert Y, Zeitler B, Miller JC, Choi VM, Jenkins SS, Wood A, Cui X, Meng X, Vincent A, Lam S, Michalkiewicz M, Schilling R, Foeckler J, Kalloway S, Weiler H, Ménoret S, Anegon I, Davis GD, Zhang L, Rebar EJ, Gregory PD, Urnov FD, Jacob HJ, Buelow R. Knockout rats via embryo microinjection of zinc-finger nucleases. Science. 2009;325:433. doi: 10.1126/science.1172447.
25. Ménoret S, Iscache AL, Tesson L, Rémy S, Usal C, Osborn MJ, Cost GJ, Brüggemann M, Buelow R, Anegon I. Characterization of immunoglobulin heavy chain knockout rats. Eur J Immunol. 2010;40:2932-2941. doi: 10.1002/eji.201040939.
26. Eddahibi S, Guignabert C, Barlier-Mur AM, Dewachter L, Fadel E, Dartevelle P, Humbert M, Simonneau G, Hanoun N, Saurini F, Hamon M, Adnot S. Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation. 2006;113:1857-1864. doi: 10.1161/CIRCULATIONAHA.105.591321.
27. Gong H, Gao X, Feng S, Siddiqui MR, Garcia A, Bonini MG, Komarova Y, Vogel SM, Mehta D, Malik AB. Evidence of a common mechanism of disassembly of adherens junctions through Gα13 targeting of VE-cadherin. J Exp Med. 2014;211:579-591. doi: 10.1084/jem.20131190.
28. Weibel ER. Fifty years of Weibel-Palade bodies: the discovery and early history of an enigmatic organelle of endothelial cells. J Thromb Haemost. 2012;10:979-984. doi: 10.1111/j.1538-7836.2012.04718.x.
29. Ochoa CD, Wu S, Stevens T. New developments in lung endothelial heterogeneity: Von Willebrand factor, P-selectin, and the Weibel-Palade body. Semin Thromb Hemost. 2010;36:301-308. doi: 10.1055/s-0030-1253452.
30. Smith P, Heath D. Electron microscopy of the plexiform lesion. Thorax. 1979;34:177-186.
31. Nishimura T, Faul JL, Berry GJ, Veve I, Pearl RG, Kao PN. 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med. 2001;163:498-502. doi: 10.1164/ajrccm.163.2.2006093.
32. Paddenberg R, Stieger P, von Lilien AL, Faulhammer P, Goldenberg A, Tillmanns HH, Kummer W, Braun-Dullaeus RC. Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice. Respir Res. 2007;8:15. doi: 10.1186/1465-9921-8-15.
33. Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68:3033-3046. doi: 10.1007/s00018-011-0735-1.
34. Snider NT, Omary MB. Post-translational modifications of intermediate filament proteins: mechanisms and functions. Nat Rev Mol Cell Biol. 2014;15:163-177. doi: 10.1038/nrm3753.
35. Chung BM, Rotty JD, Coulombe PA. Networking galore: intermediate filaments and cell migration. Curr Opin Cell Biol. 2013;25:600-612. doi: 10.1016/j.ceb.2013.06.008.
36. Reynolds AM, Holmes MD, Danilov SM, Reynolds PN. Targeted gene delivery of BMPR2 attenuates pulmonary hypertension. Eur Respir J. 2012;39:329-343. doi: 10.1183/09031936.00187310.
37. Gao H, Zhang J, Liu T, Shi W. Rapamycin prevents endothelial cell migration by inhibiting the endothelial-to-mesenchymal transition and matrix metalloproteinase-2 and -9: an in vitro study. Mol Vis. 2011;17:3406-3414.
38. Wessler JD, Steingart RM, Schwartz GK, Harvey BG, Schaffer W. Dramatic improvement in pulmonary hypertension with rapamycin. Chest. 2010;138:991-993. doi: 10.1378/chest.09-2435.
39. Seyfarth HJ, Hammerschmidt S, Halank M, Neuhaus P, Wirtz HR. Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial. Pulm Circ. 2013;3:632-638. doi: 10.1086/674311.